Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes

Toxicological Sciences

Volumn 123, Issue 1, 2011, Pages 281-289

  Guo, Liang ^a   Abrams, Rory M C ^a   Babiarz, Joshua E ^a   Cohen, Jennifer D ^a   Kameoka, Sei ^a   Sanders, Martin J ^a   Chiao, Eric ^a   Kolaja, Kyle L ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

Arrhythmia; Impedance; In vitro alternatives; Predictive toxicology; Stem cell derived cardiomyocytes; Torsades de pointes

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 4 (N ETHYL N PHENYLAMINO) 1,2 DIMETHYL 6 (METHYLAMINO)PYRIMIDINIUM CHLORIDE; ACETYLSALICYLIC ACID; ACONITINE; ALFUZOSIN; AMIODARONE; AMOXICILLIN; ANTIARRHYTHMIC AGENT; ASTEMIZOLE; CAPTOPRIL; CISAPRIDE; DOFETILIDE; ERYTHROMYCIN; FLECAINIDE; FLUOXETINE; ISOPRENALINE; MOXIFLOXACIN; MYOSIN HEAVY CHAIN; MYOSIN LIGHT CHAIN; NIFEDIPINE; OUABAIN; QUINIDINE; RANOLAZINE; RO5657; ROFECOXIB; SOTALOL; TERFENADINE; THIORIDAZINE; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; CALCIUM CELL LEVEL; CARDIOTOXICITY; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; DRUG EXPOSURE; DRUG SAFETY; ELECTRIC FIELD; ELECTRODE; HEART ARRHYTHMIA; HEART BEAT; HEART CONTRACTION; HEART FUNCTION; HEART MUSCLE CELL; HEART PROARRHYTHMIA; HEART RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROELECTRODE; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; QT PROLONGATION;

ARRHYTHMIAS, CARDIAC; CELL DIFFERENTIATION; CELLS, CULTURED; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; MYOCYTES, CARDIAC; PHARMACEUTICAL PREPARATIONS; PLURIPOTENT STEM CELLS;

EID: 80052487012     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfr158     Document Type: Article

References (41)

1. Baruscotti, M., Bucchi, A., and Difrancesco, D. (2005). Physiology and pharmacology of the cardiac pacemaker ("funny" ) current. Pharmacol. Ther. 107, 59-79.
2. Bhandari, B., and Subramanian, L. (2007). Ranolazine, a partial fatty acid oxidation inhibitor, its potential benefit in angina and other cardiovascular disorders. Recent Pat. Cardiovasc. Drug Discov. 2, 35-39.
3. Braam, S. R., Tertoolen, L., van de Stolpe, A., Meyer, T., Passier, R., and Mummery, C. L. (2010). Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res. 4, 107-116.
4. Cao, F., Wagner, R. A., Wilson, K. D., Xie, X., Fu, J. D., Drukker, M., Lee, A., Li, R. A., Gambhir, S. S., Weissman, I. L., et al. (2008). Transcriptional and functional profiling of human embryonic stem cell-derived cardiomyocytes. PloS One 3, e3474.
5. Chan, T. Y. (2009). Aconite poisoning. Clin. Toxicol. (Phila.) 47, 279-285.
6. Clusin, W. T. (2003). Calcium and cardiac arrhythmias: DADs, EADs, and alternans. Crit. Rev. Clin. Lab. Sci. 40, 337-375.
7. Crumb, W. J., Jr., Ekins, S., Sarazan, R. D., Wikel, J. H., Wrighton, S. A., Carlson, C., and Beasley, C. M., Jr.. (2006). Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis. Pharm. Res. 23, 1133-1143.
8. Csete, M. (2010). Translational prospects for human induced pluripotent stem cells. Regen. Med. 5, 509-519.
9. Davila, J. C., Cezar, G. G., Thiede, M., Strom, S., Miki, T., and Trosko, J. (2004). Use and application of stem cells in toxicology. Toxicol. Sci. 79, 214-223.
10. De Ponti, F., Poluzzi, E., Cavalli, A., Recanatini, M., and Montanaro, N. (2002). Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf. 25, 263-286.
11. Demiryurek, A. T., and Demiryurek, S. (2005). Cardiotoxicity of digitalis glycosides: roles of autonomic pathways, autacoids and ion channels. Auton. Autacoid Pharmacol. 25, 35-52.
12. Extramiana, F., Maison-Blanche, P., Cabanis, M. J., Ortemann-Renon, C., Beaufils, P., and Leenhardt, A. (2005). Clinical assessment of drug-induced QT prolongation in association with heart rate changes. Clin. Pharmacol. Ther. 77, 247-258.
13. Frothingham, R. (2001). Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 21, 1468-1472.
14. Giaever, I., and Keese, C. R. (1993). A morphological biosensor for mammalian cells. Nature 366, 591-592.
15. Giorgi, M. A., Bolanos, R., Gonzalez, C. D., and Di Girolamo, G. (2010). QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications. Curr. Drug Saf. 5, 54-57.
16. Hescheler, J., Halbach, M., Egert, U., Lu, Z. J., Bohlen, H., Fleischmann, B. K., and Reppel, M. (2004). Determination of electrical properties of ES cellderived cardiomyocytes using MEAs. J. Electrocardiol. 37(Suppl.), 110-116.
17. Hove-Madsen, L., Llach, A., Molina, C. E., Prat-Vidal, C., Farre, J., Roura, S., and Cinca, J. (2006). The proarrhythmic antihistaminic drug terfenadine increases spontaneous calcium release in human atrial myocytes. Eur. J. Pharmacol. 553, 215-221.
18. Jonsson, M. K., Duker, G., Tropp, C., Andersson, B., Sartipy, P., Vos,M. A., and van Veen, T. A. (2010). Quantified proarrhythmic potential of selected human embryonic stem cell-derived cardiomyocytes. Stem Cell Res. 4, 189-200.
19. Ju, Y. K., Gage, P. W., and Saint, D. A. (1996). Tetrodotoxin-sensitive inactivation-resistant sodium channels in pacemaker cells influence heart rate. Pflugers Arch. 431, 868-875.
20. Kattman, S. J., Koonce, C. H., Swanson, B. J., and Anson, B. D. (2011). Stem cells and their derivatives: a renaissance in cardiovascular translational research. J. Cardiovasc. Transl. Res. 4, 66-72.
21. Lacerda, A. E., Kuryshev, Y. A., Chen, Y., Renganathan, M., Eng, H., Danthi, S. J., Kramer, J. W., Yang, T., and Brown, A. M. (2008). Alfuzosin delays cardiac repolarization by a novel mechanism. J. Pharmacol. Exp. Ther. 324, 427-433.
22. Lawrence, C. L., Bridgland-Taylor, M. H., Pollard, C. E., Hammond, T. G., and Valentin, J. P. (2006). A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes. Br. J. Pharmacol. 149, 845-860.
23. Lawrence, C. L., Pollard, C. E., Hammond, T. G., and Valentin, J. P. (2005). Nonclinical proarrhythmia models: predicting Torsades de Pointes. J. Pharmacol. Toxicol. Methods 52, 46-59.
24. Lawrence, C. L., Pollard, C. E., Hammond, T. G., and Valentin, J. P. (2008). In vitro models of proarrhythmia. Br. J. Pharmacol. 154, 1516-1522.
25. Martin, R. L., McDermott, J. S., Salmen, H. J., Palmatier, J., Cox, B. F., and Gintant, G. A. (2004). The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J. Cardiovasc. Pharmacol. 43, 369-379.
26. Masumiya, H., Saito, M., Ito, M., Matsuda, T., Noguchi, K., Iida-Tanaka, N., Tanaka, H., and Shigenobu, K. (2004). Lack of action potential-prolonging effect of terfenadine on rabbit myocardial tissue preparations. Biol. Pharm. Bull. 27, 131-135.
27. Meyer, T., Leisgen, C., Gonser, B., and Gunther, E. (2004). QT-screen: highthroughput cardiac safety pharmacology by extracellular electrophysiology on primary cardiac myocytes. Assay Drug Dev. Technol. 2, 507-514.
28. Ming, Z., and Nordin, C. (1995). Terfenadine blocks time-dependent Ca2+, Na+, and K+ channels in guinea pig ventricular myocytes. J. Cardiovasc. Pharmacol. 26, 761-769.
29. Mousavizadeh, K., Ghafourifar, P., and Sadeghi-Nejad, H. (2002). Calcium channel blocking activity of thioridazine, clomipramine and fluoxetine in isolated rat vas deferens: a relative potency measurement study. J. Urol. 168, 2716-2719.
30. Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000). Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56-67.
31. Peng, S., Lacerda, A. E., Kirsch, G. E., Brown, A. M., and Bruening-Wright, A. (2010). The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. J. Pharmacol. Toxicol. Methods 61, 277-286.
32. Poluzzi, E., Raschi, E., Motola, D., Moretti, U., and De Ponti, F. (2010). Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the U.S. FDA Adverse Event Reporting System. Drug Saf. 33, 303-314.
33. Redfern, W. S., Carlsson, L., Davis, A. S., Lynch, W. G., MacKenzie, I., Palethorpe, S., Siegl, P. K., Strang, I., Sullivan, A. T., Wallis, R., et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32-45.
34. Rotstein, D. M., Gabriel, S. D., Makra, F., Filonova, L., Gleason, S., Brotherton-Pleiss, C., Setti, L. Q., Trejo-Martin, A., Lee, E. K., Sankuratri, S., et al. (2009). Spiropiperidine CCR5 antagonists. Bioorg. Med. Chem. Lett. 19, 5401-5406.
35. Roy, M., Dumaine, R., and Brown, A. M. (1996). HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 94, 817-823.
36. Sager, P. T. (2008). Key clinical considerations for demonstrating the utility of preclinical models to predict clinical drug-induced torsades de pointes. Br. J. Pharmacol. 154, 1544-1549.
37. Singh, B. N., and Wadhani, N. (2004). Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs. J. Cardiovasc. Pharmacol. Ther. 9. (Suppl. 1), S85-S97.
38. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872.
39. Xi, B., Yu, N., Wang, X., Xu, X., and Abassi, Y. A. (2008). The application of cell-based label-free technology in drug discovery. Biotechnol. J. 3, 484-495.
40. Xu, X. Q., Soo, S. Y., Sun, W., and Zweigerdt, R. (2009). Global expression profile of highly enriched cardiomyocytes derived from human embryonic stem cells. Stem Cells 27, 2163-2174.
41. Yoshida, Y., and Yamanaka, S. (2010). iPS cells: a source of cardiac regeneration. Circulation 122 80-87.